ORIGINAL RESEARCH article
Front. Med.
Sec. Intensive Care Medicine and Anesthesiology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1650118
This article is part of the Research TopicExtracorporeal Organ Support: Innovations and Challenges in Critical CareView all 7 articles
Hemoadsorption in Critically Ill Neonatal and Pediatric Patients: A Retrospective Cohort Study from a Latin American Tertiary Center
Provisionally accepted
Byron Enrique Piñeres-Olave*
Jhojan Sebastian Herrera-VargasDaniel TibaduizaAlejandro Marin-AgudeloMaría Piedad SarmientoSandra SalazarLaura Niño-JaimesNatalia Arango-Mesa- Clínica Somer, Rionegro, Colombia
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
ABSTRACT Introduction Extracorporeal blood purification therapies, such as hemoadsorption, are increasingly utilized in intensive care to modulate inflammation, improve organ function, and reduce vasoactive support. However, data on their use in neonatal and pediatric populations remain limited, particularly in low-resource settings. This study aimed to evaluate clinical and laboratory outcomes in critically ill pediatric patients receiving hemoadsorption therapy alongside extracorporeal organ support. Methods We conducted a single-center retrospective cohort study in a tertiary neonatal and pediatric intensive care unit in Latin America. Eleven critically ill patients received hemoadsorption using CytoSorb® or Oxiris® in combination with continuous renal replacement therapy (CRRT) and/or extracorporeal membrane oxygenation (ECMO). We assessed organ dysfunction scores (PELOD-2), vasoactive-inotropic score (VIS), inflammatory markers (CRP, lactate), oxygenation parameters, and liver and hematologic profiles before and after therapy. Results Hemoadsorption was associated with reductions in PELOD-2 (median 11 to 7; p=0.036) and VIS (median 75 to 6; p=0.014). Lactate levels decreased significantly (p<0.001), and oxygenation improved (PaO₂/FiO₂, median 69 to 104; p=0.042). CRP levels declined without reaching statistical significance. Liver and hematologic markers remained largely unchanged. 28-day-mortality was 54.5%. Discussion Hemoadsorption in conjunction with CRRT and/or ECMO showed potential to improve hemodynamic stability, oxygenation, and inflammation in critically ill pediatric patients. These findings support further investigation of hemoadsorption as an adjunctive therapy in pediatric critical care, especially in resource-limited environments.
Keywords: Neonatal and Pediatric Patients, septic shock, ARDS, CRRT, ECMO, Hemoadsorption, CytoSorb
Received: 19 Jun 2025; Accepted: 15 Sep 2025.
Copyright: © 2025 Piñeres-Olave, Herrera-Vargas, Tibaduiza, Marin-Agudelo, Sarmiento, Salazar, Niño-Jaimes and Arango-Mesa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Byron Enrique Piñeres-Olave, bpineres@clinicasomer.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.